Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$37.69

-0.025 (-0.07%)

12:59
09/23/18
09/23
12:59
09/23/18
12:59

AstraZeneca CEO warns of medicine shortages following Brexit, Reuters reports

Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the EU after Brexit, according to Reuters, citing a CEO's interview with the Sunday Times. "We have products that go back and forth between the UK and Europe at different stages of manufacturing," Pascal Soriot was quoted as saying. "If drugs are stuck, you have a problem." []:[https://www.reuters.com/article/us-britain-eu-astrazeneca/astrazeneca-ceo-warns-of-medicine-shortages-after-brexit-sunday-times-idUSKCN1M20Y9?feedType=RSS&feedName=businessNews]

AZN AstraZeneca
$37.69

-0.025 (-0.07%)

09/05/18
PIPR
09/05/18
NO CHANGE
Target $48
PIPR
Overweight
Biohaven deal with AstraZeneca enhances leadership, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says Biohaven Pharmaceutical (BHVN) has licensed a Phase III-ready central nervous system asset from AstraZeneca (AZN) that appears to have $500M-plus potential and "further broadens the company's pipeline." Based on his follow-up with management, the analyst believes the upfront cash payment is modest and that the Phase III trial will be efficient and require an estimated additional spend of $20M. Van Buren thinks the deal is an "attractively structured, efficient and opportunistic" that enhances Biohaven's leadership in CNS drug development. He keeps an Overweight rating on the shares with a $48 price target.
09/06/18
HCWC
09/06/18
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright impressed by Checkpoint Therapeutics' first clinical data
H.C. Wainwright analyst Joseph Pantginis says Checkpoint Therapeutics' (CKPT) first clinical data in its history "did not disappoint." The data show a "significant clinical benefit" from CK-101 treatment, Pantginis tells investors in a research note. With these safety and efficacy data in hand, Checkpoint's CK-101 may show competitive clinical advantages versus approved EGFR therapies, including AstraZeneca's Tagrisso, at least in the non-small-cell lung carcinoma indication, the analyst contends. He's "impressed" with the data and notes that Checkpoint management has confirmed its intention to move into a pivotal study in 2019 mimicking the Tagrisso Flaura study. Pantginis has a Buy rating on Checkpoint Therapeutics with an $11 price target.
09/14/18
ROTH
09/14/18
NO CHANGE
Target $33
ROTH
Buy
Roth Capital remains bullish on Stemline after AstraZeneca's Lumoxiti approved
Roth Capital analyst Jotin Marango said he had viewed the BLA review for AstraZeneca's (AZN) Lumoxiti for Hairy Cell Leukemia as a relative gauge of what might happen with Stemline's (STML) Elzonris given what he sees as the similarities between the agents. Lumoxiti's approval makes him more bullish on Stemline ahead of the Q1 of 2019 PDUFA date for Elzonris, said Marango, who raised his assumed probability of success for its BLA to 90% from 75%. He raised his price target on Stemline shares to $33 from $30 and keeps a Buy rating on the stock.
09/17/18
PIPR
09/17/18
NO CHANGE
Target $35
PIPR
Neutral
Piper sees Astra's Lynparza as 'much cleaner' than Tesaro's Zejula
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $35 price target on Tesaro (TSRO) after analyzing a year's worth of adverse event reporting as captured by FDA's Adverse Event Reporting System database, which he obtained through a Freedom of Information Act request. The analyst, while cautioning that the database "likely contains inaccuracies and is far from perfect," is "struck by how much cleaner" AstraZeneca's (AZN) Lynparza appears versus Tesaro's Zejula and Clovis Oncology's (CLVS) Rubraca. Further, Raymond is also surprised that Zejula's adverse events rates do not appear to have decreased in any meaningful way year-over-year, despite Tesaro's active down-dosing efforts. Since the analyst thinks PARPi differentiation remains largely around safety, he lowered his Zejula estimates in 2019 and beyond. Lynparza is likely to maintain the upper hand, Raymond tells investors in a research note.

TODAY'S FREE FLY STORIES

HMHC

Houghton Mifflin

$8.94

0.52 (6.18%)

12:37
02/20/19
02/20
12:37
02/20/19
12:37
Hot Stocks
Houghton Mifflin Harcourt launches HMH Audio in-house audio production studio »

Houghton Mifflin Harcourt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

EA

Electronic Arts

$99.25

-3.73 (-3.62%)

, ATVI

Activision Blizzard

$43.82

-0.66 (-1.48%)

12:35
02/20/19
02/20
12:35
02/20/19
12:35
On The Fly
Game On: An exclusive talk with Beamdog CEO Trent Oster »

'NEVERWINTER NIGHTS'…

EA

Electronic Arts

$99.25

-3.73 (-3.62%)

ATVI

Activision Blizzard

$43.82

-0.66 (-1.48%)

TTWO

Take-Two

$89.77

-3.52 (-3.77%)

NTDOY

Nintendo

$0.00

(0.00%)

MSFT

Microsoft

$106.99

-0.77 (-0.71%)

SNE

Sony

$46.86

0.65 (1.41%)

TCEHY

Tencent

$0.00

(0.00%)

UBSFY

Ubisoft

$0.00

(0.00%)

CCOEY

Capcom

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 12

    Mar

  • 13

    Mar

  • 18

    Mar

12:35
02/20/19
02/20
12:35
02/20/19
12:35
General news
FOMC minutes preview: the minutes will be scrutinized »

FOMC minutes preview: the…

OSPN

OneSpan

$20.13

3.355 (20.00%)

12:33
02/20/19
02/20
12:33
02/20/19
12:33
Downgrade
OneSpan rating change  »

Imperial downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 12

    Mar

  • 28

    Mar

OSPN

OneSpan

$20.21

3.435 (20.48%)

12:28
02/20/19
02/20
12:28
02/20/19
12:28
Downgrade
OneSpan rating change  »

OneSpan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 12

    Mar

  • 28

    Mar

KMI

Kinder Morgan

$19.20

0.05 (0.26%)

12:27
02/20/19
02/20
12:27
02/20/19
12:27
Hot Stocks
Kinder Morgan Chairman Richard Kinder buys over 19K shares of company stock »

Kinder Morgan Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

NYT

New York Times

$32.02

0.06 (0.19%)

12:25
02/20/19
02/20
12:25
02/20/19
12:25
Hot Stocks
New York Times publisher responds to Trump's 'enemy of the people' tweet »

After President Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

RTTR

Ritter Pharmaceuticals

$0.66

-0.0104 (-1.55%)

12:25
02/20/19
02/20
12:25
02/20/19
12:25
Conference/Events
Ritter Pharmaceuticals to host conference call »

Expert call with Dr Chey,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

ZNGA

Zynga

$5.09

-0.01 (-0.20%)

12:20
02/20/19
02/20
12:20
02/20/19
12:20
Options
Defensive option play in Zynga as shares ease off 52-week highs »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 11

    Mar

HSY

Hershey

$109.97

0.275 (0.25%)

12:19
02/20/19
02/20
12:19
02/20/19
12:19
Earnings
Hershey issues long-term adjusted EPS growth target of 6%-8% »

Hershey in conference…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

MCS

Marcus

$40.59

1 (2.53%)

12:18
02/20/19
02/20
12:18
02/20/19
12:18
Hot Stocks
Marcus raises quarterly dividend 6.7% to 16c per share »

Directors of The Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 02

    Apr

  • 02

    Apr

  • 06

    Jun

HSY

Hershey

$109.95

0.255 (0.23%)

12:18
02/20/19
02/20
12:18
02/20/19
12:18
Hot Stocks
Hershey would consider debt to EBITDA ratio over 2.0 times for acquisition »

Hershey in conference…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
02/20/19
02/20
12:17
02/20/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
02/20/19
02/20
12:16
02/20/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
02/20/19
02/20
12:15
02/20/19
12:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

CVS

CVS Health

$64.92

-5 (-7.15%)

, TSLA

Tesla

$302.25

-3.31 (-1.08%)

12:11
02/20/19
02/20
12:11
02/20/19
12:11
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks opened little…

CVS

CVS Health

$64.92

-5 (-7.15%)

TSLA

Tesla

$302.25

-3.31 (-1.08%)

BMY

Bristol-Myers

$51.21

-0.14 (-0.27%)

CELG

Celgene

$91.25

0.54 (0.60%)

KNDI

Kandi Technologies

$8.45

2.52 (42.50%)

GRMN

Garmin

$82.11

11.145 (15.71%)

NVTA

Invitae

$18.55

2.06 (12.49%)

OMI

Owens & Minor

$6.48

-1.46 (-18.39%)

WIX

Wix.com

$110.43

-15.275 (-12.15%)

CXO

Concho Resources

$114.44

-6.51 (-5.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 12

    Mar

  • 18

    Mar

  • 18

    Mar

  • 19

    Mar

  • 18

    May

  • 20

    May

  • 22

    May

  • 28

    May

HSY

Hershey

$110.01

0.315 (0.29%)

12:09
02/20/19
02/20
12:09
02/20/19
12:09
Hot Stocks
Hershey reaffirms 2019 guidance at CAGNY Conference »

Hershey said that in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

KNX

Knight-Swift

$34.96

0.73 (2.13%)

12:05
02/20/19
02/20
12:05
02/20/19
12:05
Options
Knight Transportation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

12:05
02/20/19
02/20
12:05
02/20/19
12:05
General news
U.S. corporate bond update: the calendar remains active. »

U.S. corporate bond…

DNLI

Denali Therapeutics

$21.44

-0.16 (-0.74%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Denali granted orphan status for mucopolysaccharidosis treatment »

The FDA granted Denali…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDY

Dr. Reddy's

$35.97

-0.45 (-1.24%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Dr. Reddy's announces re-launch of buprenorphine, naloxone sublingual film »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

HSY

Hershey

$109.86

0.165 (0.15%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Earnings
Hershey backs FY19 adjusted EPS growth view of 5%-7%, consensus $5.64 »

Backs FY19 net sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

QTT

Qutoutiao

$12.66

0.25 (2.01%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Downgrade
Qutoutiao rating change  »

Qutoutiao downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

BHC

Bausch Health

$23.23

-1.94 (-7.71%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Bausch Health falls -7.7% »

Bausch Health is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

IDT

IDT Corp

$6.48

-0.68 (-9.50%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
IDT Corp falls -9.1% »

IDT Corp is down -9.1%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.